GlassScriptPhysician profile
Erin Hector
NPI 1215551338
$14,212.00
in general payments reported to CMS, 2019-2025
26 companies · $1,946 in 2025
The $1,946 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,469 · 2022: $3,264 · 2023: $3,316 · 2024: $4,216 · 2025: $1,946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,032 · Education: $447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,031.61 |
| Education | $446.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,450.02 | 2021-2025 | |
| Abbvie INC. | $1,938.43 | 2021-2025 | |
| Janssen Biotech, INC. | $1,726.70 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $1,113.93 | 2021-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $953.76 | 2022-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $721.76 | 2023-2025 | |
| Dermavant Sciences, INC. | $717.20 | 2022-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $674.87 | 2021-2025 | Absorica Ld, Winlevi, Ilumya |
| Leo Pharma INC. | $556.53 | 2022-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $529.41 | 2023-2025 | Zoryve |
| Incyte Corporation | $473.22 | 2021-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $467.42 | 2021-2025 | |
| Galderma Laboratories, L.P. | $376.92 | 2021-2025 | Aklief |
| Ucb, INC. | $317.03 | 2021-2025 | Bimzelx |
| Amgen INC. | $233.59 | 2022-2025 | Otezla, Otezla |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $223.86 | 2021-2022 | |
| Lilly USA, LLC | $187.79 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $147.33 | 2021-2025 | |
| Organon LLC | $113.94 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $78.95 | 2021-2023 | Jublia, Arazlo |
| Botanix Sb INC | $63.72 | 2025 | Sofdra |
| Revance Therapeutics, INC. | $43.45 | 2025 | Daxxify |
| Epi Health, LLC | $32.43 | 2022 | |
| Almirall LLC | $26.27 | 2022 | |
| Sanofi-Aventis U.S. LLC | $23.48 | 2021 | |
| Verrica Pharmaceuticals INC. | $19.99 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Hector listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.